Biostage (OTCMKTS:BSTG) Releases Quarterly Earnings Results

Biostage (OTCMKTS:BSTG) posted its quarterly earnings results on Tuesday. The company reported ($0.37) EPS for the quarter, Bloomberg Earnings reports.

Shares of OTCMKTS BSTG traded up $0.02 during midday trading on Wednesday, hitting $2.33. The company’s stock had a trading volume of 227 shares, compared to its average volume of 2,913. Biostage has a 1-year low of $0.75 and a 1-year high of $3.75. The business has a fifty day simple moving average of $2.25. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.81 and a current ratio of 1.81.

Separately, ValuEngine raised shares of Biostage from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.

About Biostage

Biostage, Inc, a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants. It is developing bioengineered organ implants, which addresses the damage of the esophagus, bronchus, and trachea due to cancer, infection, trauma, or congenital abnormalities.

Read More: Fundamental Analysis

Earnings History for Biostage (OTCMKTS:BSTG)

Receive News & Ratings for Biostage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostage and related companies with MarketBeat.com's FREE daily email newsletter.